Literature DB >> 3602941

C-reactive protein in the assessment of disease activity in juvenile rheumatoid arthritis and juvenile spondyloarthritis.

A Hussein, J Stein, J H Ehrich.   

Abstract

Disease activity in 31 children with JRA and 12 with JSA was investigated clinically and by serial measurements of serum CRP and ESR over a one-year period. Prior mean duration of disease was 4.3 years. There was a significant correlation of CRP with ESR and both parameters correlated significantly with clinical disease activity. CRP concentrations and ESR in active disease were significantly higher than in moderately active and inactive disease, though neither parameter showed any significant difference between moderately active and inactive disease. Clinical scoring was more sensitive in detection of moderate disease activity than were CRP and ESR. However, in systemic JRA without articular involvement, laboratory parameters were more useful for assessing disease activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3602941     DOI: 10.3109/03009748709102914

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

Review 1.  Juvenile rheumatoid arthritis--assessment.

Authors:  T B Graham; E H Giannini
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis.

Authors:  Hyun-Ja Lim; Young-Im Moon; Myeong Soo Lee
Journal:  Rheumatol Int       Date:  2005-01-14       Impact factor: 2.631

3.  Differences in HLA-B27 positive and negative patients with ankylosing spondylitis: study of clinical disease activity and concentrations of serum IgA, C reactive protein, and haptoglobin.

Authors:  T L Reynolds; M A Khan; S van der Linden; R P Cleveland
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

4.  Tai chi for disease activity and flexibility in patients with ankylosing spondylitis--a controlled clinical trial.

Authors:  Eun-Nam Lee; Young-Hee Kim; Won Tae Chung; Myeong Soo Lee
Journal:  Evid Based Complement Alternat Med       Date:  2007-07-13       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.